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Abstract
Background: AP65 is a prominent adhesin of Trichomonas vaginalis that mediates binding of
parasites to host vaginal epithelial cells (VECs). AP65 with no secretion signal sequence, membrane
targeting peptide, and anchoring motif was recently found to be secreted.
Results: We first wanted to demonstrate surface association of AP65 to the parasite followed by
the identification of the binding epitope interacting with both organisms and VECs. AP65 was found
to bind to trichomonads, but not to trypsin-treated parasites, in an auto-ligand assay, suggesting the
existence of a surface protein associating with AP65. Since rabbit antiserum IgG antibodies reactive
with epitopes localized to the N-terminal region of AP65 inhibit the attachment of live parasites to
VECs, we hypothesized that the binding domain was localized to this region. We subcloned five
overlapping fragments of AP65 called c1 through c5, and expression of recombinant clones was
confirmed with antibodies to AP65. Each purified recombinant protein was then tested for binding
activity using an established ligand assay, and fragment c1 with the first twenty-five amino acids in
the N-terminal domain was required for binding to VECs and, surprisingly, also to parasites.
Importantly, c1 competed with the binding of AP65 to both cells types.
Conclusion: T. vaginalis AP65 is a secreted, surface-associated protein and a model is proposed
to explain how this secreted protein functions as an adhesin.
Background
Trichomonas vaginalis causes trichomonosis, the most
common, non-viral sexually transmitted infection (STI) in
humans [1]. This STI poses a risk for adverse health con-
sequences in both women and men. Adverse pregnancy
outcomes, cervical neoplasia, atypical pelvic inflamma-
tory disease are serious adverse outcomes for women [2-
4]. Complications related to trichomonal infection in
men are non-gonoccocal urethritis, prostatitis, epydi-
dymitis, urethral disease, and infertility [4-8], and recently
a relationship between trichomonosis and prostate cancer
has been shown [9]. Furthermore, increased risk for HIV
acquisition and seroconversion has been well docu-
mented in both women and men [10-13].
T. vaginalis has increased ability to cytoadhere to epithelial
versus fibroblast cells [14], and it is now accepted that pre-
paratory to successful host infection and pathogenesis is
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adhesion of T. vaginalis to vaginal epithelial cells (VECs)
[15-21]. Five different adhesin proteins (AP120, AP65,
AP33, AP51, and AP23) mediate adherence to VECs, are
members of multigene families, and except for one AP51
gene, are coordinately up-regulated by iron in medium,
lactoferrin-iron, and heme-iron [15,18,19,22-31]. Inter-
estingly, laboratory-adapted T. vaginalis isolates synthe-
size lower amounts of adhesins and have lost the ability
to up-regulate synthesis by iron [29]. Fresh clinical isolate
trichomonads immediately upon adherence to VECs but
not HeLa cells display a dramatic change in morphology
concomitant with synthesis and surface placement of
adhesins [17], and this was more recently confirmed by
analysis of the numerous trichomonad genes up-regu-
lated upon contact with VECs [20]. The adhesins AP120,
AP65, AP33, and AP51 were found to have sequence iden-
tity to metabolic enzymes [19,24-28,31], which reside
within the hydrogenosome [32].
AP65 is the hydrogenosomal NAD-dependent decarboxy-
lating malic enzyme and is a prominent trichomonad
adhesin [18]. This conclusion is based on several lines of
evidence. First, there is a direct relationship between the
amount of AP65 bound to VECs and levels of adherence
compared to other adhesins [18]. Second, polyamine
depletion increased levels of adherence up to 20-fold, and
most of this increased adherence was abrogated by anti-
AP65 antibody [21]. Third, the genetic approaches involv-
ing antisense decreased expression of ap65 [16] and heter-
ologous expression of T. vaginalis AP65 in T. foetus [23]
reaffirmed the role of AP65 in adherence. More recently
analysis of the proteins secreted during growth of T. vagi-
nalis  parasites revealed numerous metabolic enzymes,
among which included AP65. It is noteworthy that AP65
of the secreted protein preparation was found capable of
being internalized by VECs, and this resulted in signaling
of VECs for expression of genes, which included IL-8 and
COX-2 [33]. Episomal expression of AP65 within epithe-
lial cells confirmed a role for AP65 within cells in up-reg-
ulating expression of genes [33]. Therefore, as AP65
appears to play a role in establishment of infection and
host response and given the significance of trichomonosis
as a major STI, it is necessary to continue to characterize
this adhesin and identify receptor-binding epitopes for
possible future interference strategies.
In previous work, we have demonstrated that anti-AP65
serum IgG antibodies inhibit adherence of live parasites.
Further, the mapping of the antibody-binding epitopes of
AP65 revealed a cluster of epitopes at the amino terminus
of AP65 [18]. Therefore, we hypothesized that the recep-
tor-binding epitope of AP65 was localized to the N-termi-
nal region of the protein. In this study we confirmed that
cytoadherence to VECs by T. vaginalis requires protein syn-
thesis and surface placement of adhesins on trichomon-
ads and showed that AP65 binds to trichomonads, but
not trypsin-treated parasites, in an auto-ligand assay. Fur-
thermore, purified recombinant overlapping fragments of
AP65 tested for binding activity in a ligand assay showed
that a complete N-terminal domain was required for
binding to both VECs and parasites. A working model is
proposed to explain how this secreted trichomonad pro-
tein associates with surface membranes and functions as
an adhesin.
Results
Binding to VECs requires protein synthesis and surface 
proteins
We wanted to confirm that cytoadherence to VECs by T.
vaginalis requires protein synthesis and surface placement
of adhesins on trichomonads [14,19,22,29]. We per-
formed an adherence assay with cycloheximide and/or
trypsin-treated parasites. As shown in this representative
experiment in Figure 1, compared to control, untreated
trichomonads (bar Con), inhibition of protein synthesis
with cycloheximide for 30 min prior to the adherence
assay resulted in a 70% decrease in binding of trichomon-
ads to fixed VEC monolayers (bar C). This result affirms
previous data that showed prerequisite synthesis of adhes-
ins for optimal attachment of organisms to host cells [17].
Further, pretreatment of parasites with trypsin alone
caused a ~90% decrease in binding (bar T), again affirm-
ing involvement of surface proteins in adherence
[14,17,22,29]. Treatment with both cycloheximide and
trypsin further reduced parasite binding to VECs by 95%
(bar C+T). The data for each condition was statistically
significant, and as indicated by the asterisks above the
bars, all were p < 0.05. The standard deviation for each
condition never exceeded 5% of the mean. These treat-
ments did not affect parasite viability and motility. These
data show that both de novo synthesis of proteins coupled
with surface placement is necessary for optimal attach-
ment to host cells by trichomonads [17,18].
AP65 associates with fixed T. vaginalis organisms
Fluorescence with non-permeabilized trichomonads and
immunocytochemical experiments using polyclonal and
monoclonal antibody (mAb) detect AP65 on the surface
[15,18,30]. AP65 is also one of numerous proteins
secreted by the parasite [33]. Therefore, we examined the
association of exogenous AP65 in a detergent extract to
fixed T. vaginalis organisms using an auto-ligand assay
similar to a ligand assay employed with VECs (Methods).
As seen in Figure 2, immunoblots after SDS-PAGE with
mAb DM116 detected AP65 from parasite lysate that
bound to fixed trichomonads (lane 1). Organisms first
pretreated with trypsin to remove surface proteins fol-
lowed by the auto-ligand assay had no detectable AP65
bound (lane 2). As a control to show that the AP65 band
in lane 1 was due to binding of exogenous AP65 withBMC Microbiology 2007, 7:116 http://www.biomedcentral.com/1471-2180/7/116
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fixed parasites and not due to the release of any AP65
from the fixed trichomonads, an additional experiment
was performed. In this case fixed trichomonads alone
were boiled followed by SDS-PAGE and immunoblotting.
As seen in lane 3, no AP65 or crossreactive protein was
detected, showing that the AP65 band seen in lane 1 is
from bound exogenous AP65. The absence of bound
AP65 on trypsinized parasites strongly indicates a protein-
aceous site on the surface to accommodate the exoge-
nously bound AP65. These data further support the idea
that AP65 detected by fluorescence and immunocyto-
chemical assays may in part be due to the association of
secreted AP65 with the parasite surface.
AP65 recombinant fragments react with mAb and 
polyclonal antibodies to AP65
We wanted to determine the receptor-binding epitope
interacting with both trichomonads and VECs. Overlap-
ping fragments of the ap65-3 gene as illustrated in Figure
3 were cloned in the pET-26b(+) vector that contains a C-
terminal His·Tag® and expressed in E. coli Tuner™ cells.
Figure 4 (part A) shows a Coomassie blue-stained gel of
the purified AP65 recombinant clones (lanes c1 through
c5), and band intensities indicate equivalent amounts of
purified proteins were added to each lane. The same
amounts were used for immunoblots after SDS-PAGE in
part B, which shows reactivities of the five recombinant
Diagram representing the AP65-3 recombinant clones Figure 3
Diagram representing the AP65-3 recombinant 
clones. Clones c1 through c5 represent individual recom-
binant fragments cloned in pET26b(+) vector (Novagen EMD 
Chemicals Inc) using primers indicated in Table 1. Each 
recombinant fragment contains a C-terminal His·Tag® used 
for purification. The AP65 protein is illustrated above the 
clones, and numbers indicate the relative positions of amino 
acids. R is the relative position of rabbit antiserum reactive 
epitopes, and M and M' refer to epitopes reactive with mAbs 
12G4 and F11, respectively, as determined before [18].
Representative experiment showing pretreatment of para- sites with cycloheximide and/or trypsin abolishes adherence  to VECs Figure 1
Representative experiment showing pretreatment of 
parasites with cycloheximide and/or trypsin abolishes 
adherence to VECs. T. vaginalis were incubated in the 
presence or absence of cycloheximide (C), trypsin (T) or the 
combination of both (C+T) for 30 and 15 min. Treatment 
and adherence assays were performed as described in Mate-
rials and Methods. This graph is a representative experiment 
of three independent experiments with eight samples per 
experiment. For each experiment, statistical analysis using 
the t-test was performed, and error bars indicate the stand-
ard deviation for each condition. An asterisk above the bars 
indicates the p values were all less than 0.05.
Representative immunoblot showing native AP65 binds to  fixed parasites Figure 2
Representative immunoblot showing native AP65 
binds to fixed parasites. Control, untreated T. vaginalis 
(lane 1) and trypsin-treated parasites (lane 2) were fixed and 
incubated with detergent lysate of T. vaginalis isolate T016 
(extract) for 2 h at RT. After extensive washing, bound pro-
tein was released from the fixed organisms by boiling in elec-
trophoresis detergent buffer [41] and subjected to SDS-
PAGE in an 8% acrylamide gel prior to blotting onto nitrocel-
lulose. Blots were probed with mAb DM116 to AP65. Exoge-
nous AP65 bound to control, untreated parasites (lane 1) but 
not trypsin-treated organisms (lane 2). As a control, fixed 
parasites were also subjected to boiling in detergent and han-
dled identically to show no AP65 reactive protein was 
released under the same conditions (lane 3).BMC Microbiology 2007, 7:116 http://www.biomedcentral.com/1471-2180/7/116
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proteins detected by various antibodies. The recombinant
clones had reactivity according to previously-character-
ized antibody epitope mapping with the mAbs 12G4 (M)
and F11 (M'), as illustrated in Figure 3[18]. Polyclonal
1375 is a newly-generated polyclonal rabbit antiserum to
AP65. This data indicates that recombinant proteins were
expressed and represent fragments based on the AP65 pro-
tein. Further, recombinant proteins are readily detected
with antibodies essential for probing in subsequent ligand
and auto-ligand assays.
Recombinant subclone c1 binds to VECs and T. vaginalis
In order to identify the receptor-binding domain of AP65,
the purified AP65 recombinant protein fragments were
used in a ligand assay with MS-74 VECs and T. vaginalis.
Figure 5 (panel A1) shows results from a representative
immunoblot after SDS-PAGE of recombinant protein that
bound to MS-74 VECs, and as can be seen, clone c1 con-
taining the complete amino terminus bound to MS-74
VECs (lane c1). Interestingly, clone c2 that is missing the
first 25 amino acids as shown in Figure 3 lost complete
binding ability (lane c2). These data indicate that the 25
amino acids of the amino-terminus are essential for a
functional receptor-binding epitope for VECs. The other
recombinant fragments (c3 through c5) also did not bind
to VECs in a ligand assay performed identically as with c1.
Part B shows the relative equivalent amounts of protein
for each clone used in this experiment, as evidenced by
staining the gels after SDS-PAGE. This amount visualized
in stained gels (part B) represented one-tenth that added
to VECs in the ligand assays. In the course of this experi-
ment we performed an auto-ligand assay with fixed T. vag-
inalis  organisms followed by SDS-PAGE and
immunoblotting. The same amount of each clone as
added to VECs was incubated with trichomonads.
Remarkably, as with VECs and shown in panel A2, only
recombinant protein fragment c1 bound to trichomon-
ads. This indicates that the same recombinant fragment c1
of AP65 bound to both T. vaginalis organisms and VECs.
Recombinant subclone c1 competes with AP65 binding
Finally, since recombinant AP65 competes with the natu-
ral AP65 for binding to host cells [31], we performed a
competition experiment using clone c1 and AP65-HA
Recombinant subclone c1 binds to VECS and T. vaginalis Figure 5
Recombinant subclone c1 binds to VECS and T. vagi-
nalis. Part A shows the immunoblot of chemically-stabilized 
MS-74 VECs (A1) and T. vaginalis (A2) that were incubated 
with 10 µg of each purified recombinant clone for 1 h at RT. 
Cells were processed for the ligand assay (Materials and 
Method). After SDS-PAGE using 10% acrylamide gels, pro-
teins were transferred to PVDF membranes and probed with 
anti-Penta-His IgG mAb. Only recombinant clone c1 bound 
to fixed cells in the ligand assay for both cell types. Part B 
shows a Coomassie-blue stained gel containing 1 µg of each 
recombinant clones to illustrate that equal amounts of 
recombinant clones were added to cells in the ligand assays. Expression and antibody reactivity of the purified AP65-3  recombinant subclones shown in Figure 3 Figure 4
Expression and antibody reactivity of the purified 
AP65-3 recombinant subclones shown in Figure 3. 
Part A is a Coomassie blue-stained gel of 1 µg purified 
recombinant proteins after SDS-PAGE using 10% acrylamide 
gels. The proteins were purified with HisLink™ Protein Puri-
fication Resin. Part B shows immunoblots of the clones of 
panel A after SDS-PAGE of the recombinant fragments 
probed with anti-Penta-His IgG mAb antibodies (Anti-His), 
anti-AP65 mAbs (12G4 and F11) [18], and purified rabbit 
anti-AP65 IgG antibodies (Polyclonal 1375).BMC Microbiology 2007, 7:116 http://www.biomedcentral.com/1471-2180/7/116
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fusion protein in a ligand assay. In this experiment, fixed
MS-74 VECs were pre-incubated with recombinant clone
c1 followed by addition of detergent extract derived from
transfected parasites episomally expressing AP65-HA [23].
As seen in Figure 6 (panel A1) recombinant clone c1 pre-
vented the binding of AP65-HA in a concentration-
dependant manner (lane 4). Densitometric scanning of
these same AP65-HA immunoblot bands (panel B) for
comparison showed a 50% reduction of bound AP65-HA
in VECs pretreated with 10 µg c1 (bar 4). Scans never var-
ied more than 4% of the mean. A decrease by 50% was sta-
tistically significant (p < 0.05). Pretreatment with
recombinant clone c2 at the same concentrations had no
effect (data not shown). Likewise, competition was
observed when fixed T. vaginalis were used (panel C1, lane
3) and binding of exogenous AP65-HA was fully blocked
by pretreatment of fixed parasites with 10 µg of clone c1.
Overall, these results indicate strongly that the binding
epitope is localized to the N-terminal region of AP65, and
the first 25 amino acids of the protein are essential for
AP65 binding to both organisms and VECs. Panel A2 and
C2 show the clone c1 bound to VECs and organisms,
respectively, in these competition experiments.
Discussion
Binding of T. vaginalis to host cells requires synthesis and
surface expression of adhesins (Figure 1), in accordance
with earlier studies [14,17]. Recent data shows contact
with VECs results in the up-regulation of various tri-
chomonad proteins, among which include the tri-
chomonad adhesins [17,20]. The de novo synthesis of
proteins might include not only the adhesins but chaper-
ons or vesicle-associated proteins required to transport
the adhesins to the surface. In fact, it has been shown that
trichomonad disulfide isomerase (PDI), a protein with
multiple functions and known to be a chaperon, is also
up-regulated upon contact with VECs possibly helping in
the compartmentalization of AP65 to various sites [20].
Moreover, that AP65 was found to be secreted by T. vagi-
nalis [33] requires that we reassess the manner in which
this protein asserts its adhesive function. We hypothesized
that AP65 and possibly other adhesins represent surface-
associated enzymes bound after secretion and that possess
alternative functions as has been shown for other micro-
bial pathogens [34,35]. It is noteworthy, however, that re-
association of secreted AP65 for function need not
exclude alternative mechanisms of surface placement of
AP65. For example, two transmembrane domains have
been identified [18], which may play a role for localizing
AP65 onto the surface. If in fact there are multiple mech-
anisms at work for placing AP65 on the parasite surface,
then this may represent an adaptation that enhances the
overall functions of the adhesin-enzyme.
Clone c1 competes with AP65-HA for binding Figure 6
Clone c1 competes with AP65-HA for binding. Part A 
(panel A1) is an immunoblot of a ligand assay of MS-74 VECs 
pretreated with c1 recombinant protein for 30 min at RT fol-
lowed by the addition of trichomonad lysate containing 
AP65-HA and incubated for 1 h. After SDS-PAGE using 8% 
acrylamide gels and immunoblotting, membranes were 
probed with anti-HA mAb to detect bound AP65-HA. Puri-
fied rabbit anti-AP65 polyclonal IgG (Figure 4) was used to 
detect c1. Lane 1 is control detergent lysate of T016 isolate 
expressing AP65-HA showing wild type AP65 (lower band) 
and the episomally-expressed fusion AP65-HA (upper band). 
Lane 2 is control VECs without pretreatment with c1. Lanes 
3 and 4 are VECs pretreated with 1 µg and 10 µg of c1, 
respectively. There is visible inhibition of binding of AP65-HA 
by pretreatment with 10 µg c1. Panel A2 is an immunoblot to 
detect clone c1 from the same experiment of A1 to show 
the binding of the recombinant clone c1 to VECs. Part B is a 
densitometric scan of the AP65-HA immunoblot bands from 
part A1 to visually present quantitatively the relative percent-
age of bound AP65-HA. Error bars indicate standard devia-
tions. Competition with 10 µg was significant (p < 0.05). 
Panel C1 is an immunoblot of a ligand assay of pretreated T. 
vaginalis with c1 recombinant protein and handled identically 
as in part A. Trichomonads were incubated with 1 µg (lane 2) 
and 10 µg (lane 3) clone c1 before adding extract with AP65-
HA. Lane 1 is untreated, control trichomonads without c1 
addition. After SDS-PAGE and immunoblotting, AP65-HA 
was detected with mAb to HA. Panel C2 detects clone c1 
bound to parasites as in A2.BMC Microbiology 2007, 7:116 http://www.biomedcentral.com/1471-2180/7/116
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This data suggests the first 25 amino acids are essential to
the binding domain of AP65 that is localized at the
amino-terminus of the protein (Figure 5). Deletion of the
first 25 amino acids resulted in the complete abolishment
of binding to chemically-stabilized cells using a standard-
ized ligand assay [15,18,29] of the recombinant clones
(Figure 5). It is possible that a secondary structure formed
by these amino acids is responsible for AP65 association.
This hypothesis is supported by several observations. Two
synthetic peptides (1–16 and 14–30) comprising the first
30 amino acids of AP65 did not inhibit adherence (Mate-
rials and Methods; data not shown), and bioinformatic
analysis (The PSIPRED Protein Structure Prediction
Server, University College London) of AP65 predicted two
small helixes are formed by amino acids 8 to 11 and by
amino acids 25 to 28. As a result, the recombinant AP65
subclones lacking the 25 amino acids would be missing
the first helix, and this likely would yield improper fold-
ing of the putative binding motif. In addition, the hydro-
phobic nature of regions of AP65 [18] may have no role
in the binding of AP65 to host cells and parasites [36], and
this is illustrated by the fact that all clones possess hydro-
phobic amino acids. Yet, only one recombinant clone
bound to cell surfaces. Further, the recombinant clone c1
contains the 11–12 amino acid hydrogenosomal prese-
quence, and our recent findings suggest based on electro-
phoretic mobility that the secreted AP65 is a preprotein
with the presequence intact [33] and not processed as is
the enzymatic form found within hydrogenosomes. This
is a significant finding because it permits us understand
for the first time the difference between the hydrogeno-
somal and the surface-associated AP65.
A specific interaction between AP65 and a surface struc-
ture in both organism and host cells is demonstrated by
the inhibition of binding of AP65-HA fusion protein by
the N-terminal recombinant c1 fragment (Figure 6) and
the association of AP65 with untreated T. vaginalis, but
not with trypsinized parasites, in the auto-ligand assay
(Figure 2). Moreover, the AP65 N-terminal domain bind-
ing to both VECs and T. vaginalis suggests that such a struc-
ture (receptor) has common features in both host cells
and parasites. This suggests that the AP65 amino-terminus
domain is external on the protein in order to face the sur-
face of both organisms and host cells. Indeed, models of
the quaternary structure of malic enzymes show a tetra-
meric protein with a double dimer structure [37]. The
monomer has the N- and C-termini close to each other
and protruding outward, thereby making the amino ter-
minal domain exposed for binding. The malic enzyme
dimer that is formed by two monomers mirroring each
other would provide a basis for binding between parasite
and host cell, thus conferring the property of adherence to
the organism. Indeed, in the dimer form the N- and C-ter-
mini of each malic enzyme monomer do not interact with
each other [37]. It is conceivable, therefore, that each
AP65 surface dimer would have one amino-terminus
exposed that interacts with the parasite and a second one
interacting with the host membrane as is proposed by us
in the model presented in Figure 7. Furthermore, given the
dimeric nature of AP65 with accessible N- termini, it
stands to reason that a feature of trichomonads in suspen-
sion would be auto-agglutination. Indeed, this is exactly
what is seen among fresh clinical isolates, and immun-
ofluorescence with anti-AP65 antibody always detects
Model representing the association of secreted AP65 with  membranes Figure 7
Model representing the association of secreted AP65 
with membranes. AP65 is secreted to the extracellular 
environment and re-associates on the parasite surface. This 
figure shows a protein site on the parasite (labeled R) to 
which AP65 binds. It is probable that AP65 can re-associate 
as a monomer or a dimer. In the case of the AP65-dimer one 
amino-terminus is available to interact with the protein site 
on the parasite (R) and the second one with an equivalent 
host cell site (labeled R') forming a bridge that promotes 
adherence.BMC Microbiology 2007, 7:116 http://www.biomedcentral.com/1471-2180/7/116
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AP65 parasite-parasite, membrane-membrane regions
[15]. Interestingly, laboratory-adapted batch culture tri-
chomonads unable to up-regulate expression of adhesins
and that synthesize significant lower amounts of adhes-
ins, including AP65 [29], display little or no self-aggluti-
nation.
As mentioned above, housekeeping enzymes of patho-
genic organisms are secreted and are anchorless, surface-
associated proteins [34,35]. Interestingly, the mechanism
of secretion of some of these enzymes is unknown, and
enzymes have no secretion peptide signal or LPXTG
anchor motif [34,35]. T. vaginalis in fact secretes numer-
ous metabolic enzymes, including glyceraldehyde-3-
phosphate dehydrogenase, α-enolase, fructose-1-6-
biphosphate, and the adhesin AP65 into the extracellular
environment [33]. Like bacterial anchorless, surface pro-
teins, T. vaginalis secreted metabolic enzymes do not pos-
sess any known secretion peptide signal(s) or anchor
motif [33]. These characteristics clearly categorize tri-
chomonad AP65 and possibly other secreted enzymes as
members of multifunctional proteins similar to those of
other microorganisms.
Conclusion
The secretion and the absence of a covalent anchor motif
suggest that AP65 is released extracellularly and binds to
the surfaces of both organisms and VECs. Data suggests
that the first 25 amino acids of the amino terminus are
essential for the receptor-binding epitope. Once bound to
a putative receptor on parasites, AP65 could form at least
a dimer, since hydrogenosomal decarboxylating malic
enzyme-AP65 is a dimer and a tretramer [38] possessing
two amino-termini available for binding to respective par-
asite and host cell. This work permits us to generate a
model for the association of trichomonad AP65 with sur-
faces of both trichomonad and VECs (Figure 7). This
model is supported by previous data showing that poly-
clonal antibodies recognize surface AP65 and prevent
cytoadherence [15]. Furthermore, extracellular malic
decarboxylase activity identical to AP65 is present [39].
These data collectively support the idea of a protein motif,
in both VECs and T. vaginalis, binding the N-terminal
region of AP65. Further work will confirm the structure
and orientation of the AP65 on the surface of T. vaginalis.
Methods
Parasites and MS74 cell cultures
T. vaginalis isolate T016 was grown at 37°C in trypticase-
yeast-maltose (TYM) medium supplemented with 10%
heat-inactivated horse serum (HS) [40]. T016 isolate
expressing AP65-Hemagglutinin (HA) fusion protein was
generated by transfection with the pBS-ap65-3-HA-neo
plasmid, as previously described [16,23]. Stable transfect-
ants were grown at 37°C overnight (o/n) in TYM-10% HS
containing Geneticin (100 µg/lm) (GIBCO Invitrogen,
Carlsbad, CA). Only mid-logarithmic phase parasites
were used throughout.
Primary immortalized MS-74 vaginal epithelial cells
(VECs) [18] were grown at 37°C in a 5% CO2 atmosphere
in Dulbecco's Modified Eagle Medium (DMEM, GIBCO
Invitrogen) supplemented with 10% HI fetal bovine
serum (FBS), as before [18]. For the adherence assay, 5 ×
104 MS-74 cells were seeded into each well of 96-well
black, clear bottom culture plates (Corning Incorporated
Costar®, Corning, NY) and grown o/n in DMEM-10% FBS.
Cells of a confluent monolayers were washed prior to fix-
ation with 3% glutaraldehyde for 1 h at RT. Monolayers
were washed twice and blocked o/n in 0.5 M glycine.
Finally, wells were washed twice and maintained in 100 µl
of RINGER buffer (0.12 M NaCl, 3.5 mM KCl, 2 mM
CaCl2, 2.5 mM NaHCO3, pH 7.2–7.4) until use.
Adherence assay
For adherence assays, T. vaginalis organisms were grown
o/n in TYM-10% HS. Parasites were washed and sus-
pended in TYM for labeling as before [21] prior to any
treatment by adding calcein (2 µl ml-1) (Molecular
Probes™ Invitrogen, Carlsbad, CA). Then, trichomonads
were washed in RINGER buffer and suspended to 1 × 106
parasites ml-1 in TYM containing cycloheximide (20 µg
ml-1) (Sigma-Aldrich, St. Louis, MO). Cycloheximide
treatment of parasites was at 37°C for 30 min. Duplicate
cultures of 1 × 106 parasites ml-1 in TYM were treated with
bovine pancreatic type XI trypsin (1 mg ml-1) for 15 min
at 37°C. Finally, a triplicate preparation of 1 × 106 organ-
isms ml-1 was treated with cycloheximide (20 µg ml-1) for
30 min. However, at the 15 min incubation time point
with cycloheximide, trypsin (1 mg ml-1) was added and
parasites were incubated for the remaining 15 min at
37°C. Treated parasites were washed in TYM and resus-
pended in TYM to 2.5 × 106 cells ml-1. Then, 100 µl con-
taining 2.5 × 105 parasites was added to individual wells
of 96-well culture plates containing fixed confluent MS-74
VEC monolayers. After incubation for 30 min at 37°C,
wells were washed 3 times in RINGER buffer followed by
final addition of 200 µl of RINGER buffer. Fluorescence
readings were taken at 485/528 nm (excitation/emission)
in a Synergy HT plate reader (BioTek Instruments, Inc.,
Winooski, VT).
For experiments on inhibition of adherence by synthetic
peptides, custom peptides were purchased from Sigma-
Aldrich-Genosys. The peptides contained the amino-ter-
minus of AP65-3 with the amino acids sequence MLASS-
VAAPVRNICRA and CRAKLPALKTGMTLLQD. A control
peptide was also generated with random amino acids
(RLAEVKGGPPHTSDMCNWI). Synthetic peptides were
solubilized in 100% dimethylsulfoxide (DMSO) (Sigma-BMC Microbiology 2007, 7:116 http://www.biomedcentral.com/1471-2180/7/116
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Aldrich), and the peptide concentration was quantified
with BCA™ Protein Assay Kit (PIERCE, Rockford, IL). Syn-
thetic peptides were diluted in 100 mM HEPES (Sigma-
Aldrich), pH 7.5, to a stock concentration of 100 µg ml-1.
Then 0.1 ng, 1 ng and 10 ng were added to individual
wells of 96-well culture plates containing fixed 100% con-
fluent MS-74 VECs monolayers. Each condition involved
quadruplicate samples. Plates were incubated for 1 h at
37°C followed by addition of 100 µl of calcein-labeled
parasites (2.5 × 105) to individual wells. After incubation
for 20 min at 37°C, plates were washed 3 times in
RINGER buffer and handle as above.
Cloning of trichomonad AP65 recombinant fragments
T. vaginalis ap6-3 overlapping gene fragments were ampli-
fied by PCR using primers containing 5' and 3' (Table 1)
BglII restriction site. PCR products were digested and puri-
fied using a gel extraction kit (Qiagen, Inc., Valencia, CA).
PCR products were ligated into the vector pET-26b(+)
(Novagen EMD Chemicals Inc, La Jolla, CA) at a BamHI
cloning site. This vector contained a Hexa-His·Tag® at the
C-terminus for purification of the recombinant protein
fragments. Insert direction was verified by PCR using the
5' end primers and the T7 terminator universal primer
(data not shown). DH5α E. coli was transformed with
each individual plasmid by electroporation performed at
2500 V, 25 microfarads and 1000 ohms, using ECM 630
Electro cell manipulator (BTX®, Genetronics, Inc., San
Diego, CA) in 0.2 cm gap Gene Pulser® Cuvettes (BioRad
Laboratories, Hercules, CA). Plasmids were purified using
the mini prep plasmid purification kit (Qiagen, Inc.).
Expression and purification of recombinant AP65 
fragments
E. coli Tuner™ (DE3) competent cells (Novagen EMD
Chemicals Inc) were transformed with individual AP65
construct plasmids and selected with kanamycin. Single
colonies were used for culture and batch protein purifica-
tion. One hundred ml of LB containing 50 µg ml-1 kan-
amycin were inoculated with 10 ml of o/n cultures of E.
coli encoding each recombinant AP65 fragments. Cultures
were grown for 3 h at 37°C with shaking. Induction of
expression of recombinant protein was done by adding
0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG)
(Fisher Scientific, Pittsburgh, PA), and the cultures were
incubated for an additional 2.5 h at 37°C with shaking.
Pellets were collected and bacteria lysed with 10 ml lysis
buffer (50 mM sodium phosphate buffer, 50 mM Tris
HCl, pH 8.0, 0.3 M NaCl, 1% Triton ×-100, 1% deoxy-
cholic acid, and 8 M urea), sonicated for 2–5 min, and
incubated for 30 min at 37°C. Debris in the lysate was
clarified by centrifugation at 13,000 rpm for 30 min at
4°C in a Sorvall® SS-34 rotor (Thermo Fisher Scientific,
Inc. Waltham, MA). Purification of recombinant proteins
was done using HisLink™ Protein Purification Resin
(Promega, Madison, WI), according to the manufacture's
protocol. Briefly, lysate was added to 1 ml of resin and
allowed to bind for 1 h at 4°C. Resin was allowed to pre-
cipitate and washed twice with 100 mM HEPES, pH 7.5,
25 mM imidazole, 8 M urea, and once with 100 mM
HEPES, pH 7.5, 50 mM imidazole, and 8 M Urea. Finally,
recombinant protein was obtained by placing the resin in
a glass column. The bound recombinant proteins were
eluted with 3 ml of 100 mM HEPES, pH 7.5, 750 mM imi-
dazole, and 8 M urea. Purified recombinant proteins were
dialyzed to remove the urea in Slide-A-Lyzer® dialysis cas-
settes (PIERCE,) with a 10,000 MW cutoff in a stepwise
procedure. Cassettes were placed in a dialysis buffer (50
mM sodium bicarbonate, 1 mM DTT, 1 mM EDTA) con-
taining decreasing concentrations of urea as follows: i)
500 ml dialysis buffer, pH 9.0, with 4 M urea, for 1 h at
RT, ii) 500 ml dialysis buffer, pH 9.0, 2 M urea, for 2 h at
4°C, with change of buffer after an hour, iii) 200 ml dial-
ysis buffer, pH 8.3, for 1 h at 4°C, without urea, and, iv)
Table 1: Primers1 used for cloning of ap65-3 gene
Clone Primer sequence for AP65-3 Plasmid
5' c1 Bgl II GGGGAGATCTGATGCTCGCATCTTCAGTCG pET-26b(+)
3' c1 Bgl II GGGGAGATCTGGCCAGCCGTGGTAGAGTG pET-26b(+)
5' c2 Bgl II GGGGAGATCTGATGACCCTCCTTCAGG pET-26b(+)
3' c2 Bgl II GGGGAGATCTGGCCAGCCGTGGTAGAGTG pET-26b(+)
5' c3 Bgl II GGGGAGATCTGGGGAGATTCCTCTTCACACA pET-26b(+)
3' c3 Bgl II GGGGAGATCTGGGAAGCAGTTGCAGCGCCAG pET-26b(+)
5' c4 Bgl II GGGGAGATCTAATCCTCGCCGACCCA pET-26b(+)
3' c4 Bgl II GGGGAGATCTACACCCTCAAGGACGGAG pET-26b(+)
5' c5 Bgl II GGGGAGATCTGATGGTCCATGCTGACCGTA pET-26b(+)
3' c5 Bgl II GGGGAGATCTAGGTCCTTGAGCTCTGTG pET-26b(+)
5' FL NdeI GTCCAGCATATGATGCTCGCATCTTCAGTCG pBS-ap65-HA
3' FL Asp718 GTCCACGGTACCATAGTAGAGTTGCTCGTATTC pBS-ap65-HA
1 These primers were used for the cloning of overlapping fragments and full-length of the ap65-3 gene in the pET-26b(+) vector (Novagen EMD 
Chemicals Inc) in E. coli and pBS-HA vector in T. vaginalis [16, 23].BMC Microbiology 2007, 7:116 http://www.biomedcentral.com/1471-2180/7/116
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500 ml dialysis buffer, pH 9.0, o/n at 4°C without urea.
Protein concentration was quantified with the BCA™ Pro-
tein Assay Kit (PIERCE) and by SDS-PAGE.
Ligand assay and immunoblotting
This ligand assay has been extensively described
[15,18,29]. MS-74 VECs were washed in RINGER buffer
and fixed in 3% glutaraldehyde for 30 min at RT. Cells
were washed twice and blocked o/n in 0.5 M glycine. For
the ligand assay using recombinant AP65 subclones c1
through c5 (Figure 5, part A1), 10 µg of each purified
recombinant protein was added to 2 × 105 fixed MS-74
VECs and allowed to bind for 1 h at RT.
For the auto-ligand assay, the experiment was performed
using fixed trichomonads (Figure 5, part A2). In this case,
2 × 106 parasites were incubated with each clone identical
to the ligand assay described with VECs. For trypsinized
parasites (Figure 2, lane 2), 1 × 107 parasites ml-1 were first
treated with trypsin (10 mg ml-1) for 15 min at 37°C
before fixation. In addition, the auto-ligand assay was per-
formed using lysate generated from 1 × 107 T016 parasites,
as previously described [15]. This detergent extract was
incubated with 2 × 106 fixed T. vaginalis for 2 h at RT.
For competition studies with recombinant clones (Figure
6), fixed MS-74 VECs (2 × 105) and T. vaginalis (2 × 106)
were incubated with 1 µg and 10 µg of recombinant AP65
clones c1 and c2 for 30 min at RT. Lysate from 1 × 107
T016 expressing the AP65-HA fusion protein was pre-
pared as before [15], and protein concentration was deter-
mined with the BCA™ Protein Assay Kit (PIERCE). Then
10 µg of protein lysate were added to pretreated MS-74
VECs or T. vaginalis and incubated for an additional h at
RT. After incubation with lysate or recombinant protein,
cells were washed 3 times, and bound protein was solubi-
lized by boiling for 3 min in 30 µl of 2× SDS electrophore-
sis sample buffer [41]. Protein was separated on 8% or
10% acrylamide SDS-PAGE and transferred to nitrocellu-
lose or PVDF membranes (BioRad Laboratories) for
immunoblotting. Membranes were probed with mAb to
AP65 [18] and polyclonal anti-AP65 serum IgG antibod-
ies, IgG mAb to Penta-His (Qiagen, Inc.), and IgG mAb to
HA (Sigma-Aldrich). After o/n incubation with primary
antibodies, the blots were extensively washed and incu-
bated for 1 to 2 h in either secondary alkaline phos-
phatase- (AP) or horseradish peroxidase-conjugated goat
anti-mouse IgG (Sigma-Aldrich) or AP-conjugated goat
anti-rabbit IgG (BioRad Laboratories). Both primary and
secondary antibodies were used at 1:1000 dilutions.
Reproducibility of experiments
Unless otherwise stated in the text, all experiments were
performed numerous times and no less than on three dif-
ferent occasions. Statistical analysis using the t-test was
performed as needed, and as indicated with asterisks, the
p values were less than 0.05. Error bars represent standard
deviations.
Abbreviations
AP65, adhesin protein of molecular weight 65-kDa; AP65-
HA, fusion protein of AP65 and hemagglutinin (HA),
HEPES, N-2-hydroxyethyl piperazine-N' -2-ethanesul-
fonic acid; mAb, monoclonal antibody; SDS-PAGE,
sodium dodecylsulfate polyacrylamide gel electrophore-
sis; RT, room temperature; Tv, Trichomonas vaginalis VEC,
vaginal epithelial cell
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